Published in Gastroenterol Clin Biol on October 01, 1986
Endoscopic Nd:YAG laser treatment of rectosigmoid cancer. Gut (1990) 0.83
Risk factors which determine the long term outcome of Neodymium-YAG laser palliation of colorectal carcinoma. Int J Colorectal Dis (1989) 0.83
An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology (1996) 12.47
The retrieval of randomized clinical trials in liver disease from the medical literature. A comparison of MEDLARS and manual methods. Control Clin Trials (1985) 6.22
Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet (2001) 5.82
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology (1999) 5.55
Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health (2000) 3.82
Liver fibrosis in overweight patients. Gastroenterology (2000) 3.56
Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N Engl J Med (1981) 3.13
Peptic ulcer bleeding in patients with or without cirrhosis: different diseases but the same prognosis? Aliment Pharmacol Ther (2012) 2.68
Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology (1999) 2.36
Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology (2001) 2.29
Excess weight risk factor for alcoholic liver disease. Hepatology (1997) 2.22
Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology (1999) 2.18
In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A (1999) 2.17
Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology (1999) 2.11
Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med (1994) 2.05
Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut (2000) 1.94
Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat (2007) 1.86
Transforming growth factor beta and the liver. Hepatology (2001) 1.83
Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum (1999) 1.77
A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med (1992) 1.71
A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology (1991) 1.70
Modeling the hepatitis C virus epidemic in France. Hepatology (1999) 1.61
Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology (1986) 1.59
Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Am J Gastroenterol (2000) 1.57
Trends in primary liver cancer. Lancet (1998) 1.56
A two-centre, randomized, double-blind trial of ornithine oxoglutarate in 194 elderly, ambulatory, convalescent subjects. Age Ageing (1994) 1.56
A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology (1984) 1.56
Pancreatic lesions in AIDS. Lancet (1987) 1.55
Lymphadenopathy-associated virus type 2 in AIDS and AIDS-related complex. Clinical and virological features in four patients. Lancet (1987) 1.49
Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis (1999) 1.45
Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus. Gut (1999) 1.44
Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med (1992) 1.44
Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. Aliment Pharmacol Ther (2002) 1.43
Endoscopic Nd-YAG laser therapy as palliative treatment for esophageal and cardial cancer. Parameters affecting long-term outcome. Dig Dis Sci (1990) 1.43
HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat (2011) 1.43
[CagA status and virulence of Helicobacter pylori strains. Results of a French multicentric prospective study]. Gastroenterol Clin Biol (2001) 1.42
Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology (1995) 1.41
Endoscopic laser therapy for duodenal villous adenoma. Dig Dis Sci (1989) 1.38
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat (2013) 1.37
Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology (1998) 1.37
Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology (1997) 1.33
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet (2001) 1.32
In situ detection of lipid peroxidation by-products in chronic liver diseases. Hepatology (1997) 1.30
Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest. Dig Dis Sci (1994) 1.26
Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology (1996) 1.26
Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma. Aliment Pharmacol Ther (2003) 1.25
Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet (1995) 1.22
The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology (2000) 1.21
Review article: Overview of medical treatments in unresectable hepatocellular carcinoma--an impossible meta-analysis? Aliment Pharmacol Ther (1998) 1.21
In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features. J Clin Pathol (1997) 1.20
Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. J Hepatol (1998) 1.20
Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: a randomized trial. French-Speaking Club for the Study of Portal Hypertension. Eur J Gastroenterol Hepatol (1999) 1.19
Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology (1999) 1.14
Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther (1994) 1.12
Microbiology of specimens obtained by laparoscopy from controls and from patients with pelvic inflammatory disease or infertility with tubal obstruction: Chlamydia trachomatis and Ureaplasma urealyticum. Am J Obstet Gynecol (1980) 1.10
A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. J Viral Hepat (2006) 1.09
Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease. Lancet (1998) 1.08
Gastric phytobezoar destruction by Nd:YAG laser therapy. Gastrointest Endosc (1986) 1.08
Portal hypertensive colopathy. A new entity. Dig Dis Sci (1991) 1.08
Computer-aided decision support in hepatology. Scand J Gastroenterol (1992) 1.07
Multicentre study of hepatitis B virus genotypes in France: correlation with liver fibrosis and hepatitis B e antigen status. J Viral Hepat (2006) 1.06
Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe. J Viral Hepat (1999) 1.06
Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2013) 1.06
Fibrosis progression occurs in a subgroup of heavy drinkers with typical histological features. Aliment Pharmacol Ther (2007) 1.05
Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives. A case-control study. Gastroenterology (1986) 1.05
Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model. J Viral Hepat (2002) 1.03
Observer variation in assessment of liver biopsies of alcoholic patients. Alcohol Clin Exp Res (1988) 1.03
Blood oxidative stress markers are unreliable markers of hepatic steatosis. Aliment Pharmacol Ther (2006) 1.02
Worsening of steatosis and fibrosis progression. Gut (2003) 1.01
Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis. A randomized trial. J Hepatol (1988) 1.01
Preoperative predictors of blood transfusion in liver resection for tumor. Am J Surg (1997) 1.00
Adrenocorticosteroid administration and peptic ulcer: a critical analysis. J Chronic Dis (1985) 1.00
Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids. J Hepatol (2000) 0.99
Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease. Clin Res Hepatol Gastroenterol (2011) 0.98
Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus. J Clin Microbiol (1999) 0.97
Abnormal von Willebrand factor in bleeding angiodysplasias of the digestive tract. Gastroenterology (2001) 0.97